Published in Proc Natl Acad Sci U S A on February 21, 2013
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76
Genomic spectra of biliary tract cancer. Nat Genet (2015) 1.58
Recent human adaptation: genomic approaches, interpretation and insights. Nat Rev Genet (2013) 1.15
Bayesian consensus clustering. Bioinformatics (2013) 1.10
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine (2015) 1.04
NADPH oxidases: a perspective on reactive oxygen species production in tumor biology. Antioxid Redox Signal (2013) 0.99
Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. BMC Med Genomics (2013) 0.91
A network-assisted co-clustering algorithm to discover cancer subtypes based on gene expression. BMC Bioinformatics (2014) 0.89
Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLoS One (2013) 0.83
Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol Rep (2015) 0.81
Dissecting cancer heterogeneity with a probabilistic genotype-phenotype model. Nucleic Acids Res (2013) 0.81
On integrating multi-experiment microarray data. Philos Trans A Math Phys Eng Sci (2014) 0.80
Integrative omics analysis. A study based on Plasmodium falciparum mRNA and protein data. BMC Syst Biol (2014) 0.80
Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. Nat Commun (2015) 0.79
Analysis of individual protein regions provides novel insights on cancer pharmacogenomics. PLoS Comput Biol (2015) 0.79
Integrative analyses of cancer data: a review from a statistical perspective. Cancer Inform (2015) 0.79
Efficient exploration of pan-cancer networks by generalized covariance selection and interactive web content. Nucleic Acids Res (2015) 0.79
Strategies for Integrated Analysis of Genetic, Epigenetic, and Gene Expression Variation in Cancer: Addressing the Challenges. Front Genet (2016) 0.78
Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK, PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cells. Oncotarget (2015) 0.78
Statistical Methods in Integrative Genomics. Annu Rev Stat Appl (2016) 0.78
Integrative network analysis for survival-associated gene-gene interactions across multiple genomic profiles in ovarian cancer. J Ovarian Res (2015) 0.77
A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines. PLoS One (2014) 0.76
An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. J Mol Cell Biol (2015) 0.76
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov (2017) 0.75
Stepwise iterative maximum likelihood clustering approach. BMC Bioinformatics (2016) 0.75
AmalgamScope: merging annotations data across the human genome. Biomed Res Int (2014) 0.75
Integrating Epigenomics into the Understanding of Biomedical Insight. Bioinform Biol Insights (2016) 0.75
Fast dimension reduction and integrative clustering of multi-omics data using low-rank approximation: application to cancer molecular classification. BMC Genomics (2015) 0.75
Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene (2016) 0.75
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget (2016) 0.75
A non-negative matrix factorization method for detecting modules in heterogeneous omics multi-modal data. Bioinformatics (2015) 0.75
"Watching the Detectives" report of the general assembly of the EU project DETECTIVE Brussels, 24-25 November 2015. Arch Toxicol (2016) 0.75
A p-Median approach for predicting drug response in tumour cells. BMC Bioinformatics (2014) 0.75
Approaches to uncovering cancer diagnostic and prognostic molecular signatures. Mol Cell Oncol (2014) 0.75
Integrative and regularized principal component analysis of multiple sources of data. Stat Med (2016) 0.75
Efficient Drug-Pathway Association Analysis via Integrative Penalized Matrix Decomposition. IEEE/ACM Trans Comput Biol Bioinform (2016) 0.75
More Is Better: Recent Progress in Multi-Omics Data Integration Methods. Front Genet (2017) 0.75
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res (2008) 54.83
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw (2010) 38.65
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
De novo discovery of mutated driver pathways in cancer. Genome Res (2011) 2.72
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res (2005) 1.84
Integrative analysis of genome-scale data by using pseudoinverse projection predicts novel correlation between DNA replication and RNA transcription. Proc Natl Acad Sci U S A (2004) 1.47
Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci U S A (2005) 1.47
Patient-specific data fusion defines prognostic cancer subtypes. PLoS Comput Biol (2011) 1.16
p73-alpha is capable of inducing scotin and ER stress. Oncogene (2004) 1.02
Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science (1987) 0.98
Human MicroRNA targets. PLoS Biol (2004) 34.51
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
MicroRNA targets in Drosophila. Genome Biol (2003) 23.59
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
International network of cancer genome projects. Nature (2010) 20.35
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
Characterizing gene sets with FuncAssociate. Bioinformatics (2003) 14.10
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Identification of virus-encoded microRNAs. Science (2004) 12.56
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18
A novel class of small RNAs bind to MILI protein in mouse testes. Nature (2006) 8.80
The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol (2010) 7.15
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Pathguide: a pathway resource list. Nucleic Acids Res (2006) 6.05
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Protein 3D structure computed from evolutionary sequence variation. PLoS One (2011) 4.71
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev (2009) 4.43
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Direct-coupling analysis of residue coevolution captures native contacts across many protein families. Proc Natl Acad Sci U S A (2011) 4.08
Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell (2005) 3.95
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol (2009) 3.66
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood (2007) 3.64
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Automated network analysis identifies core pathways in glioblastoma. PLoS One (2010) 3.64
A series of PDB related databases for everyday needs. Nucleic Acids Res (2010) 3.60
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol (2007) 3.46
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol (2010) 3.37